1,174
edits
ACST-1: Difference between revisions
Jump to navigation
Jump to search
no edit summary
Tag: visualeditor |
No edit summary Tag: visualeditor |
||
| Line 77: | Line 77: | ||
; peri-operative mortality and morbidity (death or stroke within 30 days) at 5-years | ; peri-operative mortality and morbidity (death or stroke within 30 days) at 5-years | ||
''data expressed as % of CEA'' | ''data expressed as % of total CEA'' | ||
2.8% ( | 2.8% (2·0-3·9) vs. 4.5% (2·2-8·0) (P=NS) | ||
overall the risk per CEA was 3·1% (95% CI | overall the risk per CEA was 3·1% (95% CI 2·3-4·1) | ||
'''peri-operative mortality and morbidity (death or stroke within 30 days) at 10-years''''' | '''peri-operative mortality and morbidity (death or stroke within 30 days) at 10-years''''' | ||
''data expressed as % of CEA'' | ''data expressed as % of total CEA'' | ||
2.9% (2.1-3.8) vs. 3.6% (2.2-5.7) (P=NS) | 2.9% (2.1-3.8) vs. 3.6% (2.2-5.7) (P=NS) | ||
overall the risk per CEA was 3·0% (95% CI | overall the risk per CEA was 3·0% (95% CI 2·4-3.9) | ||
'''non-perioperative stroke risk at 5-years''' | '''non-perioperative stroke risk at 5-years''' | ||
4·1% vs. 10·0% (gain 5·9%; 95% CI | ''data expressed as events/person-years'' | ||
4·1% vs. 10·0% (gain 5·9%; 95% CI 4·0-7·8; P<0.0001) | |||
'''non-perioperative stroke risk at 10-years''' | '''non-perioperative stroke risk at 10-years''' | ||
10·8% vs. 16·9% at (gain 6·1%; 95% CI | ''data expressed as events/person-years'' | ||
10·8% vs. 16·9% at (gain 6·1%; 95% CI 2·7-9·4; P=0.0004) | |||
<!-- Ditto for secondary outcomes --> | <!-- Ditto for secondary outcomes --> | ||
; | ; | ||
=== Secondary outcomes === | |||
'''Any stroke or perioperative death at 5 years''' | |||
''data expressed as events/CEA+other events'' | |||
6·9% vs. 10·9% (gain 4·1%, 95% CI 2·0-6·2; P=0.0001) | |||
'''Any stroke or perioperative death at 10 years''' | |||
''data expressed as events/CEA+other events'' | |||
= | 13·4% vs. 17·9% (gain 4·6%, 95% CI 1·2-7·9; P=0.009) | ||
=== | ===Subgroup Analysis<!-- Was there a subgroup analysis? If so, include a summary of it here. -->=== | ||
<!-- Were there significant adverse events recorded other than those listed in the secondary outcomes? If so, list them here --> | <!-- Were there significant adverse events recorded other than those listed in the secondary outcomes? If so, list them here --> | ||